August 17, 2022 by Jason Wertheimer Sonoma Biotherapeutics Expands Board of Directors with Appointments of Katina Dorton, J.D., MBA, and John Davis, M.D., MPH Read More
June 8, 2022 by Jason Wertheimer Sonoma Biotherapeutics Announces FDA Clearance of Investigational New Drug Application for SBT115301, an Effector T Cell-Modulating Biologic for Autoimmune Diseases Read More
November 16, 2021 by Jason Wertheimer Sonoma Biotherapeutics Appoints Heidi Hagen, MBA as Chief Technical Officer Read More
September 16, 2021 by Jason Wertheimer Sonoma Biotherapeutics Expands Leadership Team with the Appointment of Doug Sheehy, J.D., as Chief Legal Officer and Secretary Read More
August 4, 2021 by Jason Wertheimer Sonoma Biotherapeutics Raises $265 Million in an Oversubscribed Series B Financing to Translate the Promise of Cell Therapy into Curative Medicines for Autoimmune and Other Inflammatory Diseases Read More
September 30, 2020 by Jason Wertheimer Sonoma Biotherapeutics Expands Series A Financing to $70 Million and Appoints Key Executives to Advance Regulatory T-cell Therapies in Autoimmune and Degenerative Diseases Read More
February 6, 2020 by Jason Wertheimer Sonoma Biotherapeutics launches with $40 million in Series A funding to advance regulatory T cell therapy in autoimmune and degenerative diseases Read More